Glenmark Pharmaceuticals Ltd.

GLENMARK

₹1891.2

0.45% (8.4)

Market Cap

₹53,346 Cr.

P/E

70.78

Key Ratios

Edit Ratio's

Market cap

53,346 Cr

70.78

Prom Holding

46.65 %

ROE (%)

11.83

ROCE (%)

22.09

Div Yield (%)

0.26

Sales

13,341 Cr

OPM (%)

17.57 %

Debt to Equity

0.25

Edit Ratio's

About

Glenmark Pharmaceuticals is a global research-led pharmaceutical company operating in Branded,… Read more

Low

1276

52W Range

High

2285

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statement

New

Edit rows

Forensics

10 Yes

Positive for this company

1 Neutral

Neutral for this company

6 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Depreciation Effect

Depreciation accounting is not leading to increase in profits
Pledge

Promoters have not pledged a significant portion of their holding
Retail Holding

Retail has been selling the stock which is usually a good time to buy
Revenue Recognition

Company is converting accounting profit to cash
Promoter Holding

Promoter has not sold any shares in the last 90 days
Other Income

Other income component is making ratios of the company look optically better

Price & Performance

Capex vs ROCE

Roce of the company has increased over the last three years
ROE

Asset turnover is responsible for roe increase over last 10 years
Share price

Share price has increased over last 10 years due to earnings
Working Capital

Working capital of the company seems to be under control
Balance Sheet Strength

Balance sheet of the company is strong. it shouldnt have solvency or liquidity issues
Current vs Historic Valuation

Company is trading at a premium to 3yr historic valuations
Debt

Company might have issues servicing its debt
Sales Growth

Sales of the company has grown at a slow pace
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong

Market Share

1.90 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

15 %

(as of Mar 18)

Source/Historic

Anti Dandruff Shampoo (Scalpe+) Market Share

2.38 %

(as of Jul 22)

Historic

Anti-Infectives - Market Share

0.35 %

(as of Nov 21)

Historic

Antineo Plastic - Market Share

4.12 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

8.80 %

(as of Nov 21)

Historic

Dermatology - Market Share

0.01 %

(as of Feb 21)

Historic

Endocrinology - Market Share

0.09 %

(as of Jul 22)

Historic

Gastro-Intestinal - Market Share

0.01 %

(as of Nov 21)

Historic

Gynecology - Market Share

0.12 %

(as of Nov 21)

Historic

Neurological - Market Share

1.40 %

(as of Nov 21)

Historic

Ophthalmology - Market Share

0.10 %

(as of Nov 21)

Historic

Pain - Market Share

2.10 %

(as of Dec 22)

Historic

Pharmaceutical Sector - Market Share

5.48 %

(as of Nov 21)

Historic

Respiratory - Market Share

0.19 %

(as of Nov 21)

Historic

Stomatological - Market Share

0.02 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

Revenue mix

Product Wise Break-Up

Product Wise Break-Up - Glenmark Pharma (Branded generics)

Location Wise Break-Up

Asset Break-Up

Operational Metrics

Number of ANDA's Filed in USA (.)
Source
Number of ANDA's Approved By USFDA (.)
Source
Domestic Sales Growth - YoY (%)
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Corporate Actions

Consolidated

DATE

DETAILS

Show Less

Suppliers

Shaily Engineering Plastics Ltd.
Borosil Renewables Ltd.
EPL Ltd.
GMM Pfaudler Ltd.
AGI Greenpac Ltd.
HLE Glascoat Ltd.
Control Print Ltd.
Gulshan Polyols Ltd.
Kilitch Drugs (India) Ltd.
Take Solutions Ltd.

Showing 5 of 10

FAQs on Glenmark Pharmaceuticals Ltd. Business

What does Glenmark Pharma do?

Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The Company is primarily engaged in the business of development, manufacturing and marketing of pharmaceutical products.

Who are the competitors of Glenmark Pharma?

Glenmark Pharma major competitors are Abbott India, Glaxosmithkline Phar, Alkem Laboratories, Aurobindo Pharma, Ipca Laboratories, Gland Pharma, Ajanta Pharma.
Market Cap of Glenmark Pharma is ₹53,346 Crs.
While the median market cap of its peers are ₹44,456 Crs.

Is Glenmark Pharma financially stable compared to its competitors?

Glenmark Pharma seems to be less financially stable compared to its competitors.
Altman Z score of Glenmark Pharma is 7.64 and is ranked 6 out of its 8 competitors.

View FAQ's On Shareprice

Global Leaders

Companies with a dominant global position in a product. Might be a sign of very strong moat.

Run Query

Superstar Favourites

Companies where superstar investors like Rakesh Jhunjhunwala, Asish Kacholia have invested

Run Query

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	May Aug	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Jun Sep Dec	Mar Jun Sep Dec
Investor Presentation	May Jul Aug	Feb Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec			Dec		Jun Sep Dec	Sep Dec	Mar		Sep	Sep
Conference Call	Mar	Mar Jun Dec	Mar Jun Sep Dec	Mar Jun Sep Dec			Jun	Mar Jun Sep Dec		Mar Jun Dec	Dec					Dec
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Glenmark Pharmaceuticals Ltd.

View the discussion on ValuePickr

Deep Dive : Why Glenmark Pharma is a GREAT Investment - Big Profits

Pharmaceuticals

How The Pharma Industry Works - PPFAS

Deep Dive into Pharma Sector - Omkara Capital

Pharma Compliance In-Depth - Amit Rajan

Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar

Nutraceuticals- Industry Overview - Value Educator

GLP-1: The Drug Redefining Diabetes, Obesity, and Pharma’s Future - Perpetuity

Generic Opportunity for Indian Pharma Companies - Anish Moonka

Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC

Ideas Dashboard

Results

Timeline

Watchlist

Portfolio

Alerts

Stock Screener

Market

Raw Material

Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd.

Key Ratios

About

Timeline

Company Timeline

Custom financial statement

Forensics

10 Yes

1 Neutral

6 No

0 No Data

Accounting & Shareholding

Contingent Liabilities

Depreciation Effect

Pledge

Retail Holding

Revenue Recognition

Promoter Holding

Other Income

Price & Performance

Capex vs ROCE

ROE

Share price

Working Capital

Balance Sheet Strength

Current vs Historic Valuation

Debt

Sales Growth

Margin Stability

ROCE Strength

Market Share

Revenue mix

Product Wise Break-Up

UNLOCK PREMIUM

Product Wise Break-Up - Glenmark Pharma (Branded generics)

UNLOCK PREMIUM

Location Wise Break-Up

UNLOCK PREMIUM

Asset Break-Up

UNLOCK PREMIUM

Operational Metrics

Peer Comparison

Corporate Actions

Suppliers

FAQs on Glenmark Pharmaceuticals Ltd. Business

What does Glenmark Pharma do?

Who are the competitors of Glenmark Pharma?

Is Glenmark Pharma financially stable compared to its competitors?

Similar Companies

Company Filing

Discussions & Analysis

SIGN UP FOR FREE